Refractory generalized pustular psoriasis - a german problem

Generalized pustular psoriasis is a rare, potentially life-threatening, autoinflammatory skin disease that is considered a special form of psoriasis vulgaris. The anti-IL-36 receptor antibody spesolimab was recently approved as a targeted treatment option for this disease for the first time. However, the Joint Federal Committee (Gemeinsamer Bundesausschuss) denied this treatment option an additional benefit compared to systemic glucocorticoids, which is why the substance is not on the market in Germany anymore. We report on a 47-year-old female patient who, after months of high-dose glucocorticoid therapy, was successfully treated with spesolimab after final approval by her health insurance company.